Do analysts prefer BDRX or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, BDRX or APVO?

Biodexa Pharmaceuticals has higher revenue and earnings than Aptevo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 2.10 -$8.42M N/A N/A Aptevo Therapeutics N/A N/A -$25.97M -$51.83 N/A

Is BDRX or APVO more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Aptevo Therapeutics N/A -201.49% -119.21%

Do analysts rate BDRX or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BDRX or GNPX?

Biodexa Pharmaceuticals has higher revenue and earnings than Genprex. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 2.10 -$8.42M N/A N/A Genprex N/A N/A -$16.23M -$133.36 N/A

Is BDRX or GNPX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Genprex N/A -163.12% -128.98%

Do analysts recommend BDRX or CRIS?

Curis has a consensus price target of $43.00, suggesting a potential upside of 3,739.29%. Given Curis' stronger consensus rating and higher possible upside, analysts clearly believe Curis is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, BDRX or CRIS?

Curis has higher revenue and earnings than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 2.10 -$8.42M N/A N/A Curis $9.44M 0.25 -$7.58M -$14.22 N/A

Which has preferable earnings and valuation, BTAI or BDRX?

Biodexa Pharmaceuticals has lower revenue, but higher earnings than BioXcel Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioXcel Therapeutics $640K 3.63 -$69.90M -$3.79 N/A Biodexa Pharmaceuticals $470K 2.10 -$8.42M N/A N/A

Is BTAI or BDRX more profitable?

Biodexa Pharmaceuticals has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics -9,549.87% N/A -185.82% Biodexa Pharmaceuticals N/A N/A N/A

Does the media favor BTAI or BDRX?

In the previous week, Biodexa Pharmaceuticals had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 7 mentions for Biodexa Pharmaceuticals and 3 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.62 beat Biodexa Pharmaceuticals' score of -0.02 indicating that BioXcel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodexa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PPCB or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, PPCB or BDRX?

Biodexa Pharmaceuticals has higher revenue and earnings than Propanc Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A Biodexa Pharmaceuticals $470K 2.10 -$8.42M N/A N/A

Is PPCB or BDRX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% Biodexa Pharmaceuticals N/A N/A N/A

Does the media favor PPCB or BDRX?

In the previous week, Biodexa Pharmaceuticals had 4 more articles in the media than Propanc Biopharma. MarketBeat recorded 7 mentions for Biodexa Pharmaceuticals and 3 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 0.17 beat Biodexa Pharmaceuticals' score of -0.02 indicating that Propanc Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biodexa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Biodexa Pharmaceuticals (BDRX) Competitors

$0.96 -0.37 (-27.82%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$0.92 -0.04 (-3.85%)

As of 06:42 AM Eastern

Compare

BDRX vs. APVO, GNPX, CRIS, BTAI, and PPCB

Should you buy Biodexa Pharmaceuticals stock or one of its competitors? Biodexa Pharmaceuticals's main competitors and comparable companies include Aptevo Therapeutics (APVO), Genprex (GNPX), Curis (CRIS), BioXcel Therapeutics (BTAI), and Propanc Biopharma (PPCB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biodexa Pharmaceuticals compare to Aptevo Therapeutics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Biodexa Pharmaceuticals has higher revenue and earnings than Aptevo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	2.10	-$8.42M	N/A	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$51.83	N/A

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Aptevo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Biodexa Pharmaceuticals had 6 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 7 mentions for Biodexa Pharmaceuticals and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.87 beat Biodexa Pharmaceuticals' score of -0.02 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Aptevo Therapeutics	Very Positive

Biodexa Pharmaceuticals' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Aptevo Therapeutics	N/A	-201.49%	-119.21%

Biodexa Pharmaceuticals has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

Summary

Biodexa Pharmaceuticals beats Aptevo Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Genprex?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Biodexa Pharmaceuticals has higher revenue and earnings than Genprex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	2.10	-$8.42M	N/A	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

Biodexa Pharmaceuticals' return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Genprex	N/A	-163.12%	-128.98%

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Genprex has a beta of -0.94, suggesting that its share price is 194% less volatile than the broader market.

In the previous week, Biodexa Pharmaceuticals had 6 more articles in the media than Genprex. MarketBeat recorded 7 mentions for Biodexa Pharmaceuticals and 1 mentions for Genprex. Genprex's average media sentiment score of 1.87 beat Biodexa Pharmaceuticals' score of -0.02 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Genprex	Very Positive

Summary

Biodexa Pharmaceuticals beats Genprex on 8 of the 9 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Curis?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Curis has a consensus price target of $43.00, suggesting a potential upside of 3,739.29%. Given Curis' stronger consensus rating and higher possible upside, analysts clearly believe Curis is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biodexa Pharmaceuticals has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Curis has a beta of 3.01, suggesting that its share price is 201% more volatile than the broader market.

In the previous week, Biodexa Pharmaceuticals had 4 more articles in the media than Curis. MarketBeat recorded 7 mentions for Biodexa Pharmaceuticals and 3 mentions for Curis. Curis' average media sentiment score of 1.63 beat Biodexa Pharmaceuticals' score of -0.02 indicating that Curis is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Curis	Very Positive

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Curis' net margin of -80.29%. Biodexa Pharmaceuticals' return on equity of 0.00% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Curis	-80.29%	-2,365.94%	-200.88%

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 5.8% of Curis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Curis has higher revenue and earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	2.10	-$8.42M	N/A	N/A
Curis	$9.44M	0.25	-$7.58M	-$14.22	N/A

Summary

Curis beats Biodexa Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

In the previous week, Biodexa Pharmaceuticals had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 7 mentions for Biodexa Pharmaceuticals and 3 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.62 beat Biodexa Pharmaceuticals' score of -0.02 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioXcel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biodexa Pharmaceuticals has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%
Biodexa Pharmaceuticals	N/A	N/A	N/A

BioXcel Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biodexa Pharmaceuticals has lower revenue, but higher earnings than BioXcel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	3.63	-$69.90M	-$3.79	N/A
Biodexa Pharmaceuticals	$470K	2.10	-$8.42M	N/A	N/A

BioXcel Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Summary

BioXcel Therapeutics beats Biodexa Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Propanc Biopharma has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 28.7% of Propanc Biopharma shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Biodexa Pharmaceuticals had 4 more articles in the media than Propanc Biopharma. MarketBeat recorded 7 mentions for Biodexa Pharmaceuticals and 3 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 0.17 beat Biodexa Pharmaceuticals' score of -0.02 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biodexa Pharmaceuticals' return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Biodexa Pharmaceuticals has higher revenue and earnings than Propanc Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Biodexa Pharmaceuticals	$470K	2.10	-$8.42M	N/A	N/A

Summary

Biodexa Pharmaceuticals beats Propanc Biopharma on 6 of the 9 factors compared between the two stocks.

Get Biodexa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDRX vs. The Competition

Export

Metric	Biodexa Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.37M	$3.85B	$7.23B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	N/A	14.33	273.89	25.33
Price / Sales	2.10	1,398.16	639.64	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	0.01	15.13	10.33	6.24
Net Income	-$8.42M	-$22.78M	$3.49B	$358.55M
7 Day Performance	45.43%	-2.50%	-0.80%	-1.20%
1 Month Performance	-32.39%	-2.84%	-1.33%	-4.26%
1 Year Performance	-97.18%	37.93%	21.15%	5.47%

Biodexa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDRX Biodexa Pharmaceuticals	0.2371 of 5 stars	$0.96 -27.8%	N/A	-96.9%	$1.37M	$470K	N/A	20	News Coverage Analyst Forecast Gap Down
APVO Aptevo Therapeutics	0.9142 of 5 stars	$1.88 +8.0%	N/A	-93.6%	$3.15M	N/A	N/A	50	Positive News
GNPX Genprex	0.547 of 5 stars	$3.54 +1.1%	N/A	-98.9%	$2.87M	N/A	N/A	20
CRIS Curis	3.1851 of 5 stars	$1.27 -5.9%	$43.00 +3,285.8%	-96.7%	$2.82M	$4.31M	N/A	60	Short Interest Decrease Gap Down
BTAI BioXcel Therapeutics	2.3086 of 5 stars	$0.07 +0.3%	$11.00 +14,744.8%	-97.5%	$2.31M	$640K	N/A	90	Short Interest Increase Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDRX) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. APVO, GNPX, CRIS, BTAI, and PPCB

How does Biodexa Pharmaceuticals compare to Aptevo Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to Genprex?

Summary

How does Biodexa Pharmaceuticals compare to Curis?

Summary

How does Biodexa Pharmaceuticals compare to BioXcel Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to Propanc Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. APVO, GNPX, CRIS, BTAI, and PPCB

How does Biodexa Pharmaceuticals compare to Aptevo Therapeutics?

Do analysts prefer BDRX or APVO?

Which has better valuation & earnings, BDRX or APVO?

Do insiders and institutionals have more ownership in BDRX or APVO?

Does the media prefer BDRX or APVO?

Is BDRX or APVO more profitable?

Which has more volatility and risk, BDRX or APVO?

Summary

How does Biodexa Pharmaceuticals compare to Genprex?

Which has higher valuation and earnings, BDRX or GNPX?

Is BDRX or GNPX more profitable?

Do insiders & institutionals have more ownership in BDRX or GNPX?

Do analysts rate BDRX or GNPX?

Which has more volatility and risk, BDRX or GNPX?

Does the media prefer BDRX or GNPX?

Summary

How does Biodexa Pharmaceuticals compare to Curis?

Do analysts recommend BDRX or CRIS?

Which has more risk & volatility, BDRX or CRIS?

Does the media favor BDRX or CRIS?

Is BDRX or CRIS more profitable?

Do insiders & institutionals have more ownership in BDRX or CRIS?

Which has better valuation and earnings, BDRX or CRIS?

Summary

How does Biodexa Pharmaceuticals compare to BioXcel Therapeutics?

Does the media favor BTAI or BDRX?

Is BTAI or BDRX more profitable?

Do analysts recommend BTAI or BDRX?

Do institutionals & insiders believe in BTAI or BDRX?

Which has preferable earnings and valuation, BTAI or BDRX?

Which has more risk and volatility, BTAI or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to Propanc Biopharma?

Do analysts rate PPCB or BDRX?

Which has more volatility and risk, PPCB or BDRX?

Do institutionals & insiders have more ownership in PPCB or BDRX?

Does the media favor PPCB or BDRX?

Is PPCB or BDRX more profitable?

Which has better valuation & earnings, PPCB or BDRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools